ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lemmer, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lemmer, J. H., Jr

Ann Thorac Surg 2000;70:S33-S37
© 2000 The Society of Thoracic Surgeons

Clinical experience in coronary bypass surgery for abciximab-treated patients

John H. Lemmer, Jr, MDa

a Legacy Good Samaritan Hospital, Northwest Surgical Associates, Portland, Oregon, USA

Address reprint requests to Dr Lemmer, 2222 NW Lovejoy, Suite 315, Portland, OR 97210
e-mail: jlemmerjr{at}aol.com

Presented at the "Managing the Patient Receiving Platelet Inhibitors in Cardiac Surgery" Roundtable Discussion, San Antonio, TX, Jan 22–23, 1999.

Abciximab effectively inhibits platelet aggregation and, therefore, there is considerable concern regarding bleeding complications in patients who require coronary artery bypass graft (CABG) surgery while affected by the drug. This presentation reviews the available published literature regarding CABG in abciximab-treated patients, the clinical results of emergency CABG in 12 patients, and management suggestions for the abciximab-treated patient requiring emergency surgery.




This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
G. Shanmugam
Tirofiban and emergency coronary surgery
Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 546 - 550.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. P. Cannon, S. R. Mehta, and S. F. Aranki
Balancing the Benefit and Risk of Oral Antiplatelet Agents in Coronary Artery Bypass Surgery
Ann. Thorac. Surg., August 1, 2005; 80(2): 768 - 779.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. W.A. Chu, S. R. Wilson, R. J. Novick, L. W. Stitt, and M. A. Quantz
Does Clopidogrel Increase Blood Loss Following Coronary Artery Bypass Surgery?
Ann. Thorac. Surg., November 1, 2004; 78(5): 1536 - 1541.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. H. Hongo, J. Ley, S. E. Dick, and R. R. Yee
The effect of clopidogrel incombination with aspirin whengiven before coronary artery bypass grafting
J. Am. Coll. Cardiol., July 17, 2002; 40(2): 231 - 237.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
T. Kovesi and D. Royston
Editorial I: Is there a bleeding problem with platelet-active drugs?
Br. J. Anaesth., February 1, 2002; 88(2): 159 - 163.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2000 by The Society of Thoracic Surgeons.